


Amendments to the Claims

Listing of Claims

1. (Currently Amended) A method for treating ~~and/or preventing~~ acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:

- a) administering a compound of formula I




I

or a pharmaceutically acceptable salt thereof; and

- b) performing a percutaneous coronary intervention procedure.

2. (Currently Amended) A method for treating ~~and/or preventing~~ acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:

- a) administering a compound of formula I




I

or a pharmaceutically acceptable salt thereof in combination with aspirin; and

- b) performing a percutaneous coronary intervention procedure.

3. (Currently Amended) A method for treating ~~and/or preventing~~ acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in the order described:

- a) first, administering a compound of formula I



I

or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin;

- b) second, performing a percutaneous coronary intervention procedure;
and
c) third, administering a compound of formula I or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin.

4. (Currently Amended) A method ~~according to Claims 2 or 3 for treating acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof,~~ comprising in order the steps of:

- a) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin about 2 to 30 days prior to performing the percutaneous coronary intervention procedure,

b) performing a percutaneous coronary intervention procedure, and

c) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin about 0 to 365 days after performance of the percutaneous coronary intervention procedure.

5. (Previously Presented) A method according to Claim 1, 2, or 3 wherein the compound of formula I, is 2-Acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride acid addition salt.

6. (Cancelled)


7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Currently Amended) ~~Use of a method of treatment for acute coronary syndrome comprising administering~~ a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, in conjunction with a stent ~~for treating and/or preventing recurrence of acute coronary syndrome.~~

11. (Currently Amended) ~~Use of a method of treatment for acute coronary syndrome comprising administering~~ a compound of formula I



I

or a pharmaceutically acceptable salt thereof, in conjunction with a percutaneous coronary intervention procedure ~~for treating and/or preventing the recurrence of acute coronary syndrome comprising administering an effective amount of said compound of formula I optionally in combination with aspirin to a patient in need thereof.~~

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)